The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit all its objectives in a ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...